GlobeNewswire by notified

Solvay to hold 2022 Annual General Meeting


Solvay to hold 2022 Annual General Meeting

Proposal to appoint two new independent directors to strengthen financial and governance expertise and enhance diversity

Brussels, April 8, 2022 - 8:30 CEST

Solvay today announced that it has published materials for its next Ordinary General Shareholders’ Meeting, which will be held on Tuesday May, 10, 2022 in Brussels, at 10.30 a.m. CEST. All documents relating to this meeting are now available on

Main agenda topics submitted to shareholders’ approval

Shareholders will be asked to vote on a number of resolutions, including the approval of the financial statements for the financial year 2021, the discharge to be given to the directors and the statutory auditor, the remuneration report and the new remuneration policy.

The Board will also propose to approve a total gross dividend of €3.85 per share. 2021 marks another year of significant progress in Solvay’s transformation journey, achieving its G.R.O.W. strategic targets three years ahead of plan, with 4% annual EBITDA growth since 2019, a Free Cash Flow conversion ratio over 30% and a 11% ROCE level. The company today is stronger on all fronts, reaching record levels in EBITDA, net profit and returns, while overcoming significant increases in raw material and energy costs.

Shareholders will also be asked to approve changes to the Board of Directors, including the appointment of two new independent director nominees, Ms. Laurence Debroux and Mr. Pierre Gurdjian for a four year term. The additions of Ms. Debroux and Mr. Gurdjian will strengthen the Board’s financial and governance expertise while enhancing the diversity of the Board.

Ms. Debroux brings to the Solvay Board significant CFO and senior executive experience at several listed companies including Heineken, JCDecaux and Sanofi, as well as her deep knowledge of finance, IT, strategy and business development. Ms. Debroux currently serves as a board member of Novo Nordisk, Exor N.V. and of Juventus Football Club S.p.A.

Mr. Gurdjian brings unique experience as a Senior Partner at McKinsey & Company as well as his deep knowledge of governance, and corporate social responsibility. He is a co-founder of Belgium’s 40 under 40, an initiative fostering a new generation of young societal leaders. He is also President of the Board of the Free University of Brussels (ULB) and a member of the board of UCB and Lhoist.

In reference to the current Board mandates, Mr Gilles Michel and Mr. Matti Lievonen will be proposed for renewal of a four-year term. Ms. Rosemary Thorne will be proposed for renewal of a one year term to ensure the smooth transition of her Board duties, particularly her role as Chair of the Audit Committee. Mr. Philippe Tournay has decided not to renew his mandate and will step down from the Board.

Nicolas Boël, Chairman of Solvay’s Board of Directors commented, “On behalf of the Board of Directors, I would like to thank Mr. Philippe Tournay for his significant contributions. We are pleased to propose the appointment of Ms. Laurence Debroux and Mr. Pierre Gurdjian and are confident that their experiences will further enhance the Board’s effectiveness at the service of Solvay’s continued future development.”

Shareholders will also be asked to vote for the appointment of Ernst & Young as new statutory auditor since the mandate of Deloitte expires at the end of this general meeting.

Meeting information

The meeting will take place at 10:30 CEST, at the Square Brussels Meeting Center, Mont des Arts B-1000 Brussels.

Only shareholders of Solvay SA who are officially recorded as such on April 26, 2022 at 12.00 p.m. CEST will have the right to participate and vote at the meeting on May 10, irrespective of the number of shares they hold on the day of the meeting.

Shareholders who wish to participate at the meeting, either in person or digitally, should declare their intentions no later than on May 4, 2022 and are required to follow the instructions indicated in the convening notice available on

The meeting will be organized in hybrid mode, both in person and digitally. Accordingly, shareholders will be able to attend the meeting physically or to exercise their rights either by granting a proxy or by participating and voting digitally in a live and interactive manner via the Lumi's AGM+ platform ( Additional details are available in the convening notice available on

Although the digital platform enables live interaction, shareholders are strongly encouraged to submit their questions in writing prior to the meeting, as this will help to ensure that answers provided at the meetings are as comprehensive and pertinent as possible. All questions can be addressed to by May 4, 2022 the latest.

Visit the Shareholders’ Meeting dedicated page for more details regarding the agenda, the admission conditions and voting methods.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ERYTECH to Present at the H.C. Wainwright Global Investment Conference17.5.2022 22:05:00 CEST | Press release

ERYTECHtoPresent at the H.C. WainwrightGlobal Investment Conference Cambridge, MA (U.S.) and Lyon (France), May 17, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that its Chief Executive Officer, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26, 2022, in Miami, USA. The corporate presentation will be held in person on Wednesday, May 25 at 10:30am ET and will be available on-line on the conference website afterwards. Mr. Beyen will be available for one-to-one meetings with investors on May 24, 25 and 26. If you would like to arrange a one-on-one meeting or register, please contact your conference representative. For more information on the H.C. Wainwright 23rd Global Investment Conference, please visit the H.C. Wainwright Conference websi


Publication on May17, 2022, after market closure Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVSCOMMUNICATES THERESULTSOFTHEORDINARYGENERAL MEETING EVS Broadcast Equipment SA, leading provider of live video production systems, held its Ordinary General Meeting on May 17, 2022. In total 73 shareholders representing 2,799,870 shares, or 19.5% of the company shares, attended by proxy the Ordinary General Meeting held physically at the company's registered office but for which the company had recommended its shareholders to attend by videoconference given the still sensitive health situation. All the resolutions have been approved, i.e.: - The remuneration report, the updated remuneration policy, the discharge of the Directors and the Auditor; - The 2021 annual accounts and the allocation of profits, including a total gross dividend of EUR 1.50 for fiscal year 2021 (such dividend is made up, on the one hand, of the i

SeaLegacy Celebrates the Inaugural Year of The Good Ocean17.5.2022 21:49:59 CEST | Press release

A unified, passionate group of businesses investing in SeaLegacy’s mission to protect the world’s oceans British Columbia, Canada, May 17, 2022 (GLOBE NEWSWIRE) -- When eight companies mostly unknown to one another came together for the first time in May of 2021, they were bound only by a commitment to protect our oceans and planet. Today, these founding members of The Good Ocean are actively supporting SeaLegacy’s commitment to ocean protection. "One of the questions I get asked the most is, 'What can I do?'" says SeaLegacy Co-Founder and President Cristina Mittermeier. "This question comes from individuals, and it also comes from businesses. Increasingly, consumers are demanding the products and services they support with their purchasing power be aligned with their desire to be accountable for their impact on earth. Members of The Good Ocean are addressing that demand and stepping into the crucial role businesses play in conservation work. Together, we are taking steps towards syste

Karolinska Development’s portfolio company Aprea Therapeutics acquires Atrin Pharmaceuticals17.5.2022 16:55:38 CEST | Press release

STOCKHOLM, SWEDEN, May 17 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has completed the acquisition of the privately-held US-based biotechnology company Atrin Pharmaceuticals Inc. Aprea Therapeutics will now prioritize the development of Atrin Pharmaceuticals’ drug candidates, which are being developed to fight cancer by affecting the proteins involved in the ability of tumors to repair damage to their DNA. With the acquisition of Atrin Pharmaceuticals’ portfolio of candidate drugs, Aprea Therapeutics intends to shift its primary focus to the development of ATRN-119, a drug candidate that inhibits an important signaling pathway in DNA damage repair. ATRN-119 will soon be evaluated in clinical phase 1/2a studies in the treatment of malignant solid tumors, both as monotherapy and in combination with standard treatment. In parallel with the development of ATRN-119, separate programs are run with a second-generation ATR i

Karolinska Developments portföljbolag Aprea Therapeutics förvärvar Atrin Pharmaceuticals17.5.2022 16:55:38 CEST | Pressemelding

STOCKHOLM, SVERIGE 17 maj 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics har förvärvat det privatägda amerikanska bioteknikbolaget Atrin Pharmaceuticals Inc. Aprea Therapeutics kommer nu att prioritera utvecklingen av Atrin Pharmaceuticals läkemedelskandidater, vilka utvecklas för att bekämpa cancersjukdomar genom att påverka de proteiner som är involverade i tumörers förmåga att reparera skador i sitt DNA. Efter förvärvet av Atrin Pharmaceuticals läkemedelsprojekt flyttar Aprea Therapeutics sitt primära fokus till utvecklingen av ATRN-119, en läkemedelskandidat som hämmar en viktig signaleringsväg vid reparation av DNA-skador. ATRN-119 kommer inom kort att börja studeras i kliniska fas 1/2a-studier vid behandling av maligna solida tumörer, både som monoterapi och i kombination med standardbehandling. Parallellt med utvecklingen av ATRN-119 bedrivs separata program med en andra generationens ATR-hämmare, ATRN-354, med poten